{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T11:21:30Z","timestamp":1792581690778,"version":"4.5.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose:<\/jats:title>\n            <jats:p>To evaluate the long-term changes in subfoveal choroidal thickness (SCT) in eyes with Type 3 macular neovascularization that underwent anti\u2013vascular endothelial growth factor therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>This retrospective study was performed with 47 patients diagnosed with Type 3 macular neovascularization and treated with anti\u2013vascular endothelial growth factor therapy. All the patients initially received three loading injections. The SCT was compared at diagnosis, 3 months, 12 months, and at the final follow-up visit. The velocity of changes in SCT was also compared between each period.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>The mean follow-up period was 52.1 \u00b1 11.0 months. The mean SCT was 143.3 \u00b1 51.2 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m at diagnosis, and it had significantly decreased to 128.6 \u00b1 47.4 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m at 3 months (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), 123.2 \u00b1 45.7 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m at 12 months (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001), and 110.0 \u00b1 43.0 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m at the final follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001). The mean velocity of the decrease in SCT was 4.9 \u00b1 3.9 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m per month during the first 3 months, 0.6 \u00b1 1.2 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m per month between the 3rd and the 12th months, and 0.3 \u00b1 0.3 <jats:italic toggle=\"yes\">\u00b5<\/jats:italic>m per month between the 12th month and the final follow-up. The velocity of the decrease was significantly greater during the first 3 months than during the 3rd to 12th month (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and 12th month to final follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) periods. The difference was not significant between the 3rd to 12th month and 12th months to final follow-up (<jats:italic toggle=\"yes\">P<\/jats:italic> = 0.836) periods.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion:<\/jats:title>\n            <jats:p>Subfoveal choroidal thickness continuously decreased over time, with a significant decrease of 23% noted in eyes with Type 3 macular neovascularization. The thickness rapidly decreased during the initial loading phase. Subsequently, a continuous but gradual decrease in the thickness was noted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/iae.0000000000003010","type":"journal-article","created":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T07:01:14Z","timestamp":1604300474000},"page":"1251-1258","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":7,"title":["LONG-TERM CHANGES IN CHOROIDAL THICKNESS IN EYES WITH TYPE 3 MACULAR NEOVASCULARIZATION"],"prefix":"10.1097","volume":"41","author":[{"given":"Jae Hui","family":"Kim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jong Woo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chul Gu","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250607","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1097\/00006982-200110000-00003","article-title":"Retinal angiomatous proliferation in age-related macular degeneration","volume":"21","author":"Yannuzzi","year":"2001","journal-title":"Retina"},{"key":"R2-20250607","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1097\/IAE.0b013e3181669504","article-title":"Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation","volume":"28","author":"Freund","year":"2008","journal-title":"Retina"},{"key":"R3-20250607","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00417-007-0575-8","article-title":"Subtype lesions of neovascular age-related macular degeneration in Chinese patients","volume":"245","author":"Liu","year":"2007","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R4-20250607","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1097\/IAE.0000000000000633","article-title":"Prevalence of subtypes of reticular pseudodrusen in newly diagnosed exudative age-related macular degeneration and polypoidal choroidal vasculopathy in Korean patients","volume":"35","author":"Kim","year":"2015","journal-title":"Retina"},{"key":"R5-20250607","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.ajo.2014.07.006","article-title":"The incidence of neovascular subtypes in newly diagnosed neovascular age-related macular degeneration","volume":"158","author":"Jung","year":"2014","journal-title":"Am J Ophthalmol"},{"key":"R6-20250607","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1097\/00006982-200509000-00005","article-title":"Nature and risk of neovascularization in the fellow eye of patients with unilateral retinal angiomatous proliferation","volume":"25","author":"Gross","year":"2005","journal-title":"Retina"},{"key":"R7-20250607","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1097\/IAE.0000000000002239","article-title":"Long-term visual changes in initially stronger fellow eyes in patients with unilateral type 3 neovascularization","volume":"39","author":"Kim","year":"2019","journal-title":"Retina"},{"key":"R8-20250607","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ophtha.2018.07.028","article-title":"Safety and efficacy of anti-vascular endothelial growth factor therapies for neovascular age-related macular degeneration: a report by the American Academy of Ophthalmology","volume":"126","author":"Bakri","year":"2019","journal-title":"Ophthalmology"},{"key":"R9-20250607","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1016\/j.ophtha.2012.02.022","article-title":"Subfoveal choroidal thickness after ranibizumab therapy for neovascular age-related macular degeneration: 12-month results","volume":"119","author":"Yamazaki","year":"2012","journal-title":"Ophthalmology"},{"key":"R10-20250607","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ophtha.2015.10.039","article-title":"Subfoveal choroidal thickness during aflibercept therapy for neovascular age-related macular degeneration: twelve-month results","volume":"123","author":"Koizumi","year":"2016","journal-title":"Ophthalmology"},{"key":"R11-20250607","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1136\/bjophthalmol-2015-308074","article-title":"Short-term choroidal thickness changes in patients treated with either ranibizumab or aflibercept: a comparative study","volume":"100","author":"Kim","year":"2016","journal-title":"Br J Ophthalmol"},{"key":"R12-20250607","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1097\/IAE.0000000000001480","article-title":"Macular choroidal volume changes after intravitreal bevacizumab for exudative age-related macular degeneration","volume":"37","author":"Palkovits","year":"2017","journal-title":"Retina"},{"key":"R13-20250607","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1097\/IAE.0000000000000952","article-title":"Choroidal thickness change after intravitreal anti-vascular endothelial growth factor treatment in retinal angiomatous proliferation and its recurrence","volume":"36","author":"Kim","year":"2016","journal-title":"Retina"},{"key":"R14-20250607","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1097\/IAE.0000000000002582","article-title":"Efficacy and safety of a treat-and-extend regimen with aflibercept in treatment-naive patients with type 3 neovascularization: a 52-week, single-arm, multicenter trial","volume":"40","author":"Arias","year":"2019","journal-title":"Retina"},{"key":"R15-20250607","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.ajo.2012.11.001","article-title":"Thinner choroid and greater drusen extent in retinal angiomatous proliferation than in typical exudative age-related macular degeneration","volume":"155","author":"Kim","year":"2013","journal-title":"Am J Ophthalmol"},{"key":"R16-20250607","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1097\/IAE.0000000000000086","article-title":"Subfoveal choroidal thickness in retinal angiomatous proliferation","volume":"34","author":"Yamazaki","year":"2014","journal-title":"Retina"},{"key":"R17-20250607","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ajo.2014.10.035","article-title":"Risk factors for geographic atrophy after intravitreal ranibizumab injections for retinal angiomatous proliferation","volume":"159","author":"Cho","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R18-20250607","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.ajo.2015.04.010","article-title":"Short-term changes in choroidal thickness after aflibercept therapy for neovascular age-related macular degeneration","volume":"160","author":"Kim","year":"2015","journal-title":"Am J Ophthalmol"},{"key":"R19-20250607","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1097\/IAE.0000000000000488","article-title":"Type 3 neovascularization: evolution, association with pigment epithelial detachment, and treatment response as revealed by spectral domain optical coherence tomography","volume":"35","author":"Nagiel","year":"2015","journal-title":"Retina"},{"key":"R20-20250607","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1097\/IAE.0000000000001268","article-title":"An updated staging system of type 3 neovascularization using spectral domain optical coherence tomography","volume":"36","author":"Su","year":"2016","journal-title":"Retina"},{"key":"R21-20250607","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1007\/s00417-012-2199-x","article-title":"Enhanced depth imaging of the choroid in patients with neovascular age-related macular degeneration treated with anti-VEGF therapy versus untreated patients","volume":"251","author":"Rahman","year":"2013","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R22-20250607","doi-asserted-by":"crossref","first-page":"904","DOI":"10.5301\/ejo.5000478","article-title":"Retinal and choroidal thickness changes after single anti-VEGF injection in neovascular age-related macular degeneration: ranibizumab vs bevacizumab","volume":"24","author":"Sizmaz","year":"2014","journal-title":"Eur J Ophthalmol"},{"key":"R23-20250607","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.ajo.2015.12.024","article-title":"Choroidal thickness changes in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study","volume":"164","author":"Ting","year":"2016","journal-title":"Am J Ophthalmol"},{"key":"R24-20250607","doi-asserted-by":"crossref","first-page":"7868","DOI":"10.1038\/s41598-017-08276-4","article-title":"Choroidal remodeling in age-related macular degeneration and polypoidal choroidal vasculopathy: a 12-month prospective study","volume":"7","author":"Ting","year":"2017","journal-title":"Sci Rep"},{"key":"R25-20250607","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1097\/IAE.0000000000002198","article-title":"Reduced choriocapillaris flow in eyes with type 3 neovascularization and age-related macular degeneration","volume":"38","author":"Borrelli","year":"2018","journal-title":"Retina"}],"container-title":["Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,7]],"date-time":"2025-06-07T18:04:54Z","timestamp":1749319494000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/IAE.0000000000003010"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":25,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/iae.0000000000003010","relation":{},"ISSN":["0275-004X"],"issn-type":[{"value":"0275-004X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]}}}